“We are honored to have these esteemed and accomplished scientific and clinical leaders join AltPep’s Advisory Board,” said Valerie Daggett, Ph.D., Founder and CEO of AltPep. “These individuals have each made foundational contributions to the field of neurodegenerative diseases. Their depth of expertise, together with the contributions of our current advisors, will be critical in advancing the development of our unique platform for early detection and treatment of Alzheimer’s disease and other amyloid diseases.”